These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 29693363)

  • 1. Edaravone in the treatment of amyotrophic lateral sclerosis: efficacy and access to therapy - a roundtable discussion.
    Brooks BR; Jorgenson JA; Newhouse BJ; Shefner JM; Agnese W
    Am J Manag Care; 2018 Apr; 24(9 Suppl):S175-S186. PubMed ID: 29693363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Edaravone for the treatment of amyotrophic lateral sclerosis.
    Yoshino H
    Expert Rev Neurother; 2019 Mar; 19(3):185-193. PubMed ID: 30810406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Edaravone: a new hope for deadly amyotrophic lateral sclerosis.
    Bhandari R; Kuhad A; Kuhad A
    Drugs Today (Barc); 2018 Jun; 54(6):349-360. PubMed ID: 29998226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Edaravone for amyotrophic lateral sclerosis: barriers to access and lifeboat ethics.
    Breiner A; Zinman L; Bourque PR
    CMAJ; 2020 Mar; 192(12):E319-E320. PubMed ID: 32392516
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients.
    Park JM; Kim SY; Park D; Park JS
    Neurol Sci; 2020 Jan; 41(1):119-123. PubMed ID: 31471712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease-modifying treatment of amyotrophic lateral sclerosis.
    Schultz J
    Am J Manag Care; 2018 Aug; 24(15 Suppl):S327-S335. PubMed ID: 30207671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Use and Safety of Edaravone for Amyotrophic Lateral Sclerosis in the Veterans Affairs Health Care System.
    Vu M; Tortorice K; Zacher J; Dong D; Hur K; Zhang R; Good CB; Glassman PA; Cunningham FE
    JAMA Netw Open; 2020 Oct; 3(10):e2014645. PubMed ID: 33017028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs.
    Jaiswal MK
    Med Res Rev; 2019 Mar; 39(2):733-748. PubMed ID: 30101496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Edaravone May Prevent Ferroptosis in ALS.
    Spasić S; Nikolić-Kokić A; Miletić S; Oreščanin-Dušić Z; Spasić MB; Blagojević D; Stević Z
    Curr Drug Targets; 2020; 21(8):776-780. PubMed ID: 32077821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of clinical outcome and safety profile of edaravone in treatment of amyotrophic lateral sclerosis: a 72-week single-center experience.
    Ismail II; Massoud F; Kamel WA; Al-Hashel JY
    Acta Neurol Belg; 2021 Dec; 121(6):1591-1597. PubMed ID: 32651875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Edaravone, a Free Radical Scavenger, Delayed Symptomatic and Pathological Progression of Motor Neuron Disease in the Wobbler Mouse.
    Ikeda K; Iwasaki Y
    PLoS One; 2015; 10(10):e0140316. PubMed ID: 26469273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased oxidative stress in patients with amyotrophic lateral sclerosis and the effect of edaravone administration.
    Nagase M; Yamamoto Y; Miyazaki Y; Yoshino H
    Redox Rep; 2016 May; 21(3):104-12. PubMed ID: 26191780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Edaravone Oral Suspension: A Neuroprotective Agent to Treat Amyotrophic Lateral Sclerosis.
    Singh P; Belliveau P; Towle J; Neculau AE; Dima L
    Am J Ther; 2024 May-Jun 01; 31(3):e258-e267. PubMed ID: 38691665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug Repurposing: Promises of Edaravone Target Drug in Traumatic Brain Injury.
    Shakkour Z; Issa H; Ismail H; Ashekyan O; Habashy KJ; Nasrallah L; Jourdi H; Hamade E; Mondello S; Sabra M; Zibara K; Kobeissy F
    Curr Med Chem; 2021; 28(12):2369-2391. PubMed ID: 32787753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Edaravone and its clinical development for amyotrophic lateral sclerosis.
    Takei K; Watanabe K; Yuki S; Akimoto M; Sakata T; Palumbo J
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):5-10. PubMed ID: 28872907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of a decreased anti-oxidative activity by edaravone in amyotrophic lateral sclerosis patients.
    Ohta Y; Yamashita T; Nomura E; Hishikawa N; Ikegami K; Osakada Y; Matsumoto N; Kawahara Y; Yunoki T; Takahashi Y; Takamiya M; Tadokoro K; Sasaki R; Nakano Y; Tsunoda K; Sato K; Omote Y; Takemoto M; Abe K
    J Neurol Sci; 2020 Aug; 415():116906. PubMed ID: 32446009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A perspective on therapies for amyotrophic lateral sclerosis: can disease progression be curbed?
    Xu X; Shen D; Gao Y; Zhou Q; Ni Y; Meng H; Shi H; Le W; Chen S; Chen S
    Transl Neurodegener; 2021 Aug; 10(1):29. PubMed ID: 34372914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on Antioxidant Therapy with Edaravone: Expanding Applications in Neurodegenerative Diseases.
    Yamashita T; Abe K
    Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Edaravone: A New Treatment for ALS].
    Yamashita T; Abe K
    Brain Nerve; 2019 Nov; 71(11):1245-1251. PubMed ID: 31722310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two Decades-Long Journey from Riluzole to Edaravone: Revisiting the Clinical Pharmacokinetics of the Only Two Amyotrophic Lateral Sclerosis Therapeutics.
    Dash RP; Babu RJ; Srinivas NR
    Clin Pharmacokinet; 2018 Nov; 57(11):1385-1398. PubMed ID: 29682695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.